Century Therapeutics, Inc. is a leading biotechnology company that is setting the rhythm in defining the future of cell therapy. The company's primary area of focus is on developing transformative cell therapies for cancer, using purpose-built iPSC platforms, with the goal of improving and saving lives.
Founded in 2019 and based in Philadelphia, Century stands out in its sophisticated and precise approach to oncology treatment. Its unique and innovative process involves programming induced pluripotent stem cells (iPSCs), which are adult cells that have been genetically reprogrammed back into an embryonic-like pluripotent state. By harnessing and appropriating these iPSCs, Century can manufacture any type of cell in the human body. The resultant cells have the potential to treat a variety of diseases, but Century's primary focus is on developing allogeneic cell therapies for patients suffering from cancer.
Unlike other cell therapies that are derived from the patients themselves or donors and can only be used once, Century's iPSC-derived therapies are "off-the-shelf," which means they can be mass produced and made readily available to patients who need them. This removes many logistical issues and reduces the production time and costs, making the therapies potentially more affordable and accessible.
Century's unique IPSC platform and the tremendous promise it holds in the oncology area has attracted a lot of attention in the biotech world. The company has successfully secured investment from high-profile entities such as Fujifilm Corporation and Versant Ventures.
Currently, Century Therapeutics is developing multiple "off-the-shelf" products in both the immune-oncology and hematologic malignancy spaces. They are also exploring the development of iPSC-derived chimeric antigen receptor T (CAR-T) cell therapies, which have previously shown incredible successes in treating certain types of cancers.
In a relatively short time, Century has made remarkable strides in cell and gene therapy, contributing major innovative breakthroughs. They have carved out a niche in the biotech industry, becoming leading pioneers in iPSC research and cancer cell therapy. Even still, Century Therapeutics continues to grow, innovate, and push the boundaries of what is possible in the world of cell therapy. With patient's needs at the core, they are dedicated to developing and delivering effective, accessible, and life-changing cell therapies to those in need.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends

Russotti Gregory sold 2,587 shares of Century Therapeutics (NASDAQ: IPSC) on September 14, 2026, at $1.93 per share. This transaction, classified under SEC transaction code S, represented approximately 0.5% of his prior holdings. Following the sale, Gregory retains 509,198 shares in the company.

Brent Pfeiffenberger, President and CEO of Century Therapeutics, Inc. (NASDAQ:IPSC), had 31,172 common stock shares withheld by the company on August 14, 2026. This transaction was to cover tax withholding requirements related to the vesting of restricted stock units (RSUs). After this withholding, Pfeiffenberger directly owns 3,634,302 shares of Century Therapeutics common stock.

HC Wainwright has lowered its Q3 2026 EPS forecast for Century Therapeutics (NASDAQ:IPSC) to a loss of $0.12 per share, down from a previous estimate of $0.11, while maintaining a "Buy" rating and a $5.00 price target. This revision follows Century Therapeutics reporting a Q2 loss of $0.17 per share, missing the consensus estimate of a $0.11 loss. The overall analyst consensus for IPSC is "Hold" with an average price target of $4.75, and institutional investors currently own approximately 50.2% of the company's stock.